Zimmer Biomet price target lowered to $140 from $147 at Deutsche Bank

Deutsche Bank lowered the firm’s price target on Zimmer Biomet to $140 from $147 and keeps a Hold rating on the shares. The analyst is optimistic on the company’s long-term growth and says execution will drive multiple expansion.